Essential Conversations for HCC: Radiology-Oncology Collaboration and Immunotherapy Advances in Intermediate and Advanced Disease
Essential Conversations for HCC: Radiology-Oncology Collaboration and Immunotherapy Advances in Intermediate and Advanced Disease is organized by PVI, PeerView Institute for Medical Education.
Activity Release Date: February 16, 2023
Activity Expiration Date: March 15, 2024
Activity Description:
Modern care of hepatocellular carcinoma (HCC) is increasingly reliant on collaboration between interventional radiology and oncology to select, combine, sequence, and transition between therapy options. In this activity, based on a recent webcast event, case-based discussions are used to explore best practices for managing patients through interdisciplinary collaboration. Experts discuss innovative immunotherapy and locoregional therapy options in earlier-stage disease, the transition to systemic therapy in advanced disease, and explore the latest clinical and safety data in immunotherapy-antiangiogenic regimens, dual checkpoint inhibitor approaches, and newer single-agent immune options.
Educational Objectives:
Upon completion of this activity, participants should be better able to:
• Cite current evidence supporting immunotherapy-based platforms in advanced and intermediate HCC
• Integrate immunotherapy platforms into team-based, multidisciplinary management of intermediate- and advanced-stage HCC, including via clinical trial enrollment when appropriate
• Address safety, dosing, care coordination, and therapy delivery considerations when treating patients with HCC using multimodal management options.